0001209191-17-039289.txt : 20170612
0001209191-17-039289.hdr.sgml : 20170612
20170612191654
ACCESSION NUMBER: 0001209191-17-039289
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170609
FILED AS OF DATE: 20170612
DATE AS OF CHANGE: 20170612
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kite Pharma, Inc.
CENTRAL INDEX KEY: 0001510580
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
BUSINESS PHONE: (310) 824-9999
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BUTITTA CYNTHIA M
CENTRAL INDEX KEY: 0001222082
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36508
FILM NUMBER: 17907720
MAIL ADDRESS:
STREET 1: 3165 PORTER DRIVE
CITY: PALO ALTO
STATE: CA
ZIP: 94304
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-06-09
0
0001510580
Kite Pharma, Inc.
KITE
0001222082
BUTITTA CYNTHIA M
C/O KITE PHARMA, INC.
2225 COLORADO AVENUE
SANTA MONICA
CA
90404
0
1
0
0
Chief Operating Officer
Common Stock
2017-06-09
4
M
0
10000
1.35
A
127795
D
Common Stock
2017-06-09
4
S
0
400
84.81
D
127395
D
Common Stock
2017-06-09
4
S
0
900
86.42
D
126495
D
Common Stock
2017-06-09
4
S
0
2502
87.80
D
123993
D
Common Stock
2017-06-09
4
S
0
4100
89.09
D
119893
D
Common Stock
2017-06-09
4
S
0
1698
89.76
D
118195
D
Common Stock
2017-06-09
4
S
0
400
91.08
D
117795
D
Employee Stock Option (Right to Buy)
1.35
2017-06-09
4
M
0
10000
0.00
D
2024-03-25
Common Stock
10000
115394
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 9, 2017.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.40 to $85.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.04 to $86.83, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $87.31 to $88.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.38 to $89.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.38 to $90.35, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $90.94 to $91.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
108,839 of the 435,394 shares originally subject to the stock option vested and became exercisable on December 15, 2014, and 9,071 shares vest monthly thereafter.
/s/ David M. Tanen, Attorney-in-Fact
2017-06-12